Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 12/20 | 0.98 |
| ▸ | P2RY2 | P41231 | 5/20 | 0.98 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.75 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.67 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.67 |
| ▸ | HSP90B1 | P14625 | 2/20 | 0.67 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.67 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.67 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.67 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19464861 | 0.99 | P2RY1 (1.00) | P2RY1P2RY2P2RY11ADORA3HSP90AA1 | |
| SCHEMBL14346778 | 0.93 | P2RY1 (1.00) | P2RY1P2RY2P2RY11ADORA3HSP90AA1 | |
| SCHEMBL19464862 | 0.93 | P2RY1 (1.00) | P2RY1P2RY2P2RY11ADORA3HSP90AA1 | |
| SCHEMBL12269663 | 0.93 | P2RY1 (1.00) | P2RY1P2RY2P2RY11ADORA3HSP90AA1 | |
| SCHEMBL10120961 | 0.93 | P2RY1 (1.00) | P2RY1P2RY2P2RY11ADORA3HSP90AA1 | |
| SCHEMBL21710766 | 0.91 | P2RY1 (0.83) | P2RY1P2RY2P2RY11ADORA3HSP90AA1 | |
| SCHEMBL19807382 | 0.91 | P2RY1 (0.84) | P2RY1P2RY2P2RY11ADORA3HSP90AA1 | |
| SCHEMBL10121160 | 0.90 | P2RY1 (0.82) | P2RY1P2RY2P2RY11ADORA3HSP90AA1 | |
| SCHEMBL19459472 | 0.90 | P2RY1 (0.80) | P2RY1P2RY2P2RY11ADORA3HSP90AA1 | |
| SCHEMBL19459719 | 0.89 | P2RY1 (0.81) | P2RY1P2RY2P2RY11ADORA3HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3445368-B1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | ASTROCYTE PHARMACEUTICALS INC (US) | 2024-07-17 | — | — | EP | disclosed |
| US-11839615-B2 | Compounds and methods for treating addiction and related disorders | ASTROCYTE PHARMACEUTICALS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-11839615-B2 | Compounds and methods for treating addiction and related disorders | ASTROCYTE PHARMACEUTICALS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-20230165887-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-06-01 | — | — | US | disclosed |
| US-20230165887-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-06-01 | — | — | US | disclosed |
| US-11484545-B2 | Compounds and methods for treating neurological and cardiovascular conditions | ASTROCYTE PHARMACEUTICALS, INC. (US) | 2022-11-01 | — | — | US | disclosed |
| US-20220000899-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2022-01-06 | — | — | US | disclosed |
| US-10953031-B2 | Compounds and methods for treating neurological and cardiovascular conditions | ASTROCYTE PHARMACEUTICALS, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| US-20210030760-A1 | COMPOUNDS AND METHODS FOR TREATING ADDICTION AND RELATED DISORDERS | ASTROCYTE PHARMACEUTICALS, INC. | 2021-02-04 | — | — | US | disclosed |
| US-20200046751-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | ASTROCYTE PHARMACEUTICALS, INC. | 2020-02-13 | — | — | US | disclosed |
| WO-2019157317-A1 | COMPOUNDS AND METHODS FOR TREATING ADDICTION AND RELATED DISORDERS | ASTROCYTE PHARMACEUTICALS, INC. (US) | 2019-08-15 | — | — | WO | disclosed |
| US-10265338-B2 | Compounds and methods for treating neurological and cardiovascular conditions | ASTROCYTE PHARMACEUTICALS, INC. (US) | 2019-04-23 | — | — | US | disclosed |
| US-20180021363-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | ASTROCYTE PHARMACEUTICALS, INC. | 2018-01-25 | — | — | US | disclosed |
| US-20180021363-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | ASTROCYTE PHARMACEUTICALS, INC. | 2018-01-25 | — | — | US | disclosed |
| WO-2017185061-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | ASTROCYTE PHARMACEUTICALS, INC. (US) | 2017-10-26 | — | — | WO | disclosed |
| US-9789131-B1 | Compounds and methods for treating neurological and cardiovascular conditions | ASTROCYTE PHARMACEUTICALS, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-9789131-B1 | Compounds and methods for treating neurological and cardiovascular conditions | ASTROCYTE PHARMACEUTICALS, INC. (US) | 2017-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10265338-B2 | Compounds and methods for treating neurological and cardiovascular conditions | TNNI3, CPT1B, TNNT2 | P2RY1 1828/4885P2RY2 1796/4885P2RY11 2159/4885 |
| US-11839615-B2 | Compounds and methods for treating addiction and related disorders | ADORA2A, TAAR5, ADORA3 | P2RY1 113/4885P2RY2 119/4885P2RY11 141/4885 |
| US-20180021363-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | TNNI3, CPT1B, TNNT2 | P2RY1 1828/4885P2RY2 1796/4885P2RY11 2159/4885 |
| US-10953031-B2 | Compounds and methods for treating neurological and cardiovascular conditions | TNNI3, CPT1B, TNNT2 | P2RY1 1828/4885P2RY2 1796/4885P2RY11 2159/4885 |
| US-20200046751-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | TNNI3, CPT1B, TNNT2 | P2RY1 1828/4885P2RY2 1796/4885P2RY11 2159/4885 |
| US-11484545-B2 | Compounds and methods for treating neurological and cardiovascular conditions | TNNI3, CPT1B, TNNT2 | P2RY1 1828/4885P2RY2 1796/4885P2RY11 2159/4885 |
| US-20210030760-A1 | COMPOUNDS AND METHODS FOR TREATING ADDICTION AND RELATED DISORDERS | SLC6A3, PNMT, CES2 | P2RY1 2266/4885P2RY2 1900/4885P2RY11 2031/4885 |
| US-20230165887-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | TNNI3, CPT1B, TNNT2 | P2RY1 1828/4885P2RY2 1796/4885P2RY11 2159/4885 |
| US-20220000899-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | TNNI3, CPT1B, TNNT2 | P2RY1 1828/4885P2RY2 1796/4885P2RY11 2159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.